Temporal Control of NF-κB Activation by ERK Differentially Regulates Interleukin-1β-induced Gene Expression*

In cultured rat vascular smooth muscle cells, sustained activation of ERK is required for interleukin-1β to persistently activate NF-κB. Without ERK activation, interleukin-1β induces only acute and transient NF-κB activation. The present study examined whether the temporal control of NF-κB activation by ERK could differentially regulate the expression of NF-κB-dependent genes, including inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), vascular cell adhesion molecule-1 (VCAM-1), and manganese-containing superoxide dismutase (Mn-SOD). Treatment of vascular smooth muscle cells with interleukin-1β induced the expression of iNOS, COX-2, VCAM-1, and Mn-SOD in a time-dependent manner, but with different patterns. Either PD98059 or U0126, selective inhibitors of MEK, or overexpression of a dominant negative MEK-1 inhibited interleukin-1β- induced ERK activation and the expression of iNOS and COX-2 but had essentially no effect on the expression of VCAM-1 and Mn-SOD. The expression of these genes was inhibited when NF-κB activation was down-regulated by MG132, a proteasome inhibitor, or by overexpression of an I-κBα mutant that prevented both the transient and the persistent activation of NF-κB. Inhibition of ERK did not affect interleukin-1β-induced I-κBα phosphorylation and degradation but attenuated I-κBβ degradation. Thus, although NF-κB activation was essential for interleukin-1β induction of each of the proteins studied, gene expression was differentially regulated by ERK and by the duration of NF-κB activation. These results reveal a novel functional role for ERK as an important temporal regulator of NF-κB activation and NF-κB-dependent gene expression.

[1]  A. Hoffmann,et al.  The I (cid:1) B –NF-(cid:1) B Signaling Module: Temporal Control and Selective Gene Activation , 2022 .

[2]  P. Brecher,et al.  Growth Factors Enhance Interleukin-1&bgr;-Induced Persistent Activation of Nuclear Factor-&kgr;B in Rat Vascular Smooth Muscle Cells , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[3]  T. Lawrence,et al.  Possible new role for NF-κB in the resolution of inflammation , 2001, Nature Medicine.

[4]  P. Brecher,et al.  Persistent Activation of Nuclear Factor-&kgr;B by Interleukin-1&bgr; and Subsequent Inducible NO Synthase Expression Requires Extracellular Signal-Regulated Kinase , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[5]  G. Ghosh,et al.  IκBβ, but Not IκBα, Functions as a Classical Cytoplasmic Inhibitor of NF-κB Dimers by Masking Both NF-κB Nuclear Localization Sequences in Resting Cells* , 2001, The Journal of Biological Chemistry.

[6]  G. Ghosh,et al.  Mechanism of IκBα Binding to NF-κB Dimers* , 2000, The Journal of Biological Chemistry.

[7]  J. Catravas,et al.  Non‐NF‐κB elements are required for full induction of the rat type II nitric oxide synthase in vascular smooth muscle cells , 2000 .

[8]  P. Brecher,et al.  N-Acetyl-L-cysteine potentiates interleukin-1beta induction of nitric oxide synthase : role of p44/42 mitogen-activated protein kinases. , 2000, Hypertension.

[9]  R. Sartor,et al.  The IκB/NF-κB system: a key determinant of mucosal inflammation and protection , 2000 .

[10]  J. Corbett,et al.  Prolonged STAT1 Activation Is Associated with Interferon-γ Priming for Interleukin-1-induced Inducible Nitric-oxide Synthase Expression by Islets of Langerhans* , 1999, The Journal of Biological Chemistry.

[11]  P. Brecher,et al.  N-acetyl-L-cysteine enhances interleukin-1beta-induced nitric oxide synthase expression. , 1999, Hypertension.

[12]  A. Baldwin,et al.  Synergistic activation of NF-kappaB by tumor necrosis factor alpha and gamma interferon via enhanced I kappaB alpha degradation and de novo I kappaBbeta degradation , 1997, Molecular and cellular biology.

[13]  David M. Rothwarf,et al.  A cytokine-responsive IκB kinase that activates the transcription factor NF-κB , 1997, Nature.

[14]  S. Ghosh,et al.  Role of unphosphorylated, newly synthesized I kappa B beta in persistent activation of NF-kappa B , 1996, Molecular and cellular biology.

[15]  Jonathan D. Cohen,et al.  The Cytokine Responsive Vascular Smooth Muscle Cell Enhancer of Inducible Nitric Oxide Synthase , 1995, The Journal of Biological Chemistry.

[16]  H. Erdjument-Bromage,et al.  IκB-β regulates the persistent response in a biphasic activation of NF-κB , 1995, Cell.

[17]  J. Fries,et al.  Nuclear Factor-κB Mediates Induction of Vascular Cell Adhesion Molecule-1 in Glomerular Mesangial Cells , 1995 .

[18]  C. Nathan,et al.  Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. , 1994, The Journal of biological chemistry.

[19]  A. Israël,et al.  Promoter analysis of the gene encoding the I kappa B‐alpha/MAD3 inhibitor of NF‐kappa B: positive regulation by members of the rel/NF‐kappa B family. , 1993, The EMBO journal.

[20]  Amyj . Williams,et al.  Functional analysis of the human vascular cell adhesion molecule 1 promoter , 1992, The Journal of experimental medicine.

[21]  G. Rosen,et al.  Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1). , 1992, The Journal of biological chemistry.

[22]  D. Baltimore,et al.  Activation in vitro of NF-κB" by phosphorylation of its inhibitor IκB" , 1990, Nature.

[23]  Xianglin Shi,et al.  New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. , 1999, Clinical chemistry.

[24]  A. Baldwin,et al.  THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .

[25]  P. Baeuerle,et al.  Function and activation of NF-kappa B in the immune system. , 1994, Annual review of immunology.